The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2017 | The risk of skeletal adverse events with zoledronic acid
Heinz Ludwig, MD, from the Wilhelminen Cancer Research Institute, Vienna, Austria, discusses two promising studies presented at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. The first investigated the combination of zoledronic acid and denusomab (NCT01345019). The results found that zoledronic acid reduced the risk of skeletal related adverse events, however there was a decreased risk of progression. The second study, the Cardamom trial (NCT02315716) investigated the combination of carfilzomib, cyclophosphamide, and dexamethasone. Dr Ludwig states that although not every trial shows successful results, they do offer new information.
